Asset Details

MbrlCatalogueTitleDetail

Do you wish to reserve the book?

2019 update of the EULAR recommendations for the management of systemic lupus erythematosus

by Moroni, Gabriella , Troldborg, Anne , Bertsias, George , Tesar, Vladimir , Tincani, Angela , Jayne, David , Wenzel, Jörg , Boumpas, Dimitrios T , Cervera, Ricard , Smolen, Josef S , Svenungsson, Elisabet , Kostopoulou, Myrto , Larsen, Janni L , Aringer, Martin , Boletis, John N , van Vollenhoven, Ronald , Bajema, Ingeborg , Houssiau, Frédéric , Kuhn, Annegret , Govoni, Marcello , Fanouriakis, Antonis , Alunno, Alessia , Schneider, Matthias , Doria, Andrea , Gordon, Caroline , Kouloumas, Marios , Lerstrøm, Kirsten , Mosca, Marta

in Antiphospholipid antibodies / Azathioprine / Biological Products - therapeutic use / Body weight / Cardiovascular diseases / Comorbidity / Disease Management / Disease prevention / Evidence-Based Medicine - methods / Glucocorticoids / Glucocorticoids - therapeutic use / Health risk assessment / Humans / Hydroxychloroquine / Hydroxychloroquine - therapeutic use / Immunomodulation / Immunosuppressive Agents - therapeutic use / Literature reviews / Lupus / Lupus Erythematosus, Systemic - complications / Lupus Erythematosus, Systemic - drug therapy / lupus nephritis / Management / Mental disorders / Methotrexate / Monoclonal antibodies / Mycophenolic acid / Prednisone / Recommendation / Remission / Risk factors / Rituximab / Severity of Illness Index / Systemic lupus erythematosus / treatment

2019

Yes Please

Hey, we have placed the reservation for you!

By the way, why not check out events that you can attend while you pick your title.

Oops! Something went wrong.

Looks like we were not able to place the reservation. Kindly try again later.

Are you sure you want to remove the book from the shelf?

2019 update of the EULAR recommendations for the management of systemic lupus erythematosus

2019

Confirm

Do you wish to request the book?

2019 update of the EULAR recommendations for the management of systemic lupus erythematosus

2019

Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy

How would you like to get it?

Submit

We have requested the book for you!

Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.

Oops! Something went wrong.

Looks like we were not able to place your request. Kindly try again later.

Journal Article

2019 update of the EULAR recommendations for the management of systemic lupus erythematosus

Moroni, Gabriella,

Troldborg, Anne,

Bertsias, George,

Tesar, Vladimir,

Tincani, Angela,

Jayne, David,

Wenzel, Jörg,

Boumpas, Dimitrios T,

Cervera, Ricard,

Smolen, Josef S,

Svenungsson, Elisabet,

Kostopoulou, Myrto,

Larsen, Janni L,

Aringer, Martin,

Boletis, John N,

van Vollenhoven, Ronald,

Bajema, Ingeborg,

Houssiau, Frédéric,

Kuhn, Annegret,

Govoni, Marcello,

Fanouriakis, Antonis,

Alunno, Alessia,

Schneider, Matthias,

Doria, Andrea,

Gordon, Caroline,

Kouloumas, Marios,

Lerstrøm, Kirsten,

Mosca, Marta

2019

Overview

Our objective was to update the EULAR recommendations for the management of systemic lupus erythematosus (SLE), based on emerging new evidence. We performed a systematic literature review (01/2007–12/2017), followed by modified Delphi method, to form questions, elicit expert opinions and reach consensus. Treatment in SLE aims at remission or low disease activity and prevention of flares. Hydroxychloroquine is recommended in all patients with lupus, at a dose not exceeding 5 mg/kg real body weight. During chronic maintenance treatment, glucocorticoids (GC) should be minimised to less than 7.5 mg/day (prednisone equivalent) and, when possible, withdrawn. Appropriate initiation of immunomodulatory agents (methotrexate, azathioprine, mycophenolate) can expedite the tapering/discontinuation of GC. In persistently active or flaring extrarenal disease, add-on belimumab should be considered; rituximab (RTX) may be considered in organ-threatening, refractory disease. Updated specific recommendations are also provided for cutaneous, neuropsychiatric, haematological and renal disease. Patients with SLE should be assessed for their antiphospholipid antibody status, infectious and cardiovascular diseases risk profile and preventative strategies be tailored accordingly. The updated recommendations provide physicians and patients with updated consensus guidance on the management of SLE, combining evidence-base and expert-opinion.

Share this book

Add to My Shelf

Publisher

BMJ Publishing Group Ltd and European League Against Rheumatism,Elsevier Limited

Subject

Antiphospholipid antibodies

/ Azathioprine

/ Biological Products - therapeutic use

/ Body weight

/ Cardiovascular diseases

/ Comorbidity

/ Disease Management